CoChat

2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment

Open access
Zhou, Liya, Lu, Hong, Song, Zhiqiang, Lyu, Bin, Chen, Ye, Wang, Jiyao, Xia, Jun, Zhao, Zhan, on behalf of Helicobacter Pylori Study Group of Chinese Society of Gastroenterology · 2022 · Chinese Medical Journal
Cited by 249

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Helicobacter pylori (H. pylori) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer. H. pylori eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H. pylori eradication. We aim to provide guidance on pharmacological treatment of H. pylori infection. Methods: This clinical practice guideline is developed following the World Health Organization's recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formulate clinical recommendations, minimizing bias and increasing transparency of the clinical practice guideline development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and The Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline's completeness and transparency. Results: Though decreasing in developed countries, the prevalence of H. pylori remains high in developing countries, causing a major public health burden. This clinical practice guideline contains 12 recommendations concerning pharmacological treatment for H. pylori eradication. Among them, it is worth highlighting that bismuth preparations are inexpensive, safe, and effective, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatment. In empirical treatment, high-dose dual therapy is equally effective compared with bismuth quadruple therapy. Conclusions: The 12 recommendations in this clinical practice guideline are formed with consideration for stakeholders’ values and preferences, resource use, feasibility, and acceptability. Recommendations are generalizable to resource limited settings with similar antibiotic resistance pattern as China, and lower middle-income countries facing comparable sociological and technical challenges. Registration: Guidelines International Network (GIN) website, https://guidelines.ebmportal.com/node/69996.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cm9.0000000000002546

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Zhou, L., Lu, H., Song, Z., Lyu, B., Chen, Y., Wang, J., Xia, J., Zhao, Z., & on behalf of Helicobacter Pylori Study Group of Chinese Society of Gastroenterology
Venue
Chinese Medical Journal
Published
2022-12-20
Volume
135
Issue
24
Pages
2899-2910
ISSN
  • 0366-6999 (ISSN-L)
  • 2542-5641
OpenAlex
W4313312310
Cited by
249
References
3
FWCI
37.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. https://app.cochat.ai/papers/10.1097/cm9.0000000000002546
The paper
Zhou, L., Lu, H., Song, Z., Lyu, B., Chen, Y., Wang, J., Xia, J., Zhao, Z., & on behalf of Helicobacter Pylori Study Group of Chinese Society of Gastroenterology. (2022). 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000002546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.